Literature DB >> 20661918

Acute life-threatening cardiovascular toxicity with umbilical cord blood infusion: the role of dextran.

Robert W Ma, John M Kwan, David D Ma, Keith C Fay.   

Abstract

Umbilical cord blood (UCB) is being increasingly used for hematopoietic stem cell transplantation due to its immediate availability. Dimethylsulfoxide (DMSO) and dextran-40 are commonly used for processing and cryopreservation of UCB. Adverse UCB infusion-related events are usually mild. However, reports of severe life-threatening events are now emerging. DMSO has been proposed as a possible cause of infusion-related reactions. In this report, we draw attention to an acute near-fatal reaction with UCB infusions resulting in myocardial ischemia and acute renal failure. We propose that dextran-40 in UCB infusion products be considered as a potential causative agent contributing to this infusion-related reaction, based on reports of known adverse reactions to dextran-40 in non-transplant settings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20661918     DOI: 10.1002/ajh.21797

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  3 in total

1.  A severe umbilical cord stem cell infusion reaction due to dextran in an atopic pediatric patient.

Authors:  L Cooling; A Sankar; R Mody; G Yanik; C Bonifant; S W Choi
Journal:  Bone Marrow Transplant       Date:  2017-03-06       Impact factor: 5.483

2.  Another case of acute cardiopulmonary toxicity with cord blood infusion: is dextran the culprit?

Authors:  Sung Choi; Sandra Hoffmann; Laura Cooling
Journal:  Transfusion       Date:  2012-01       Impact factor: 3.157

3.  Low rate of infusional toxicity after expanded cord blood transplantation.

Authors:  Adham S Bear; Patrick J Hanley; Doyle M Bosque; Conrad R Cruz; Indresh Kaur; Hao Liu; Partow Kebriaei; Chitra Hosing; Katayoun Rezvani; Betul Oran; Marcos J De Lima; Catherine M Bollard; Elizabeth J Shpall
Journal:  Cytotherapy       Date:  2014-02-28       Impact factor: 5.414

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.